Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies

© 2020 Wiley Periodicals LLC.

The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests is massive. The external validation of their performance is needed before use in clinical routine practice. Our study aims at assessing the analytical and clinical performance of two enzyme-linked immunosorbent assay tests detecting antibodies directed against the virus nucleocapsid protein: The NovaLisa SARS-CoV-2 immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) test (NovaTec) allowing a separate detection of each antibody and the Platelia SARS-CoV-2 Total Ab test (Bio-Rad) detecting total antibodies (IgM, IgA, and IgG). Two-hundred and eight coronavirus disease 2019 samples from 48 quantitative reverse transcription-polymerase chain reaction (RT-qPCR) confirmed patients were used to perform the sensitivity analysis. Non-SARS-CoV-2 sera (n = 79) with a potential cross-reaction to SARS-CoV-2 immunoassays were included in the specificity analysis. In addition, using receiver operator characteristic curves, adapted cut-off for improvement of the performances were proposed. The kinetics of these antibodies was also assessed over 8 weeks. Two weeks after the RT-qPCR positive detection, the NovaLisa test shows a sensitivity and specificity of 94.9% (95% confidence interval [CI]: 83.1%-98.6%) and 96.2% (95% CI: 89.4%-98.7%) for IgG, of 89.7% (95% CI: 76.4%-95.9%) and 98.7% (95% CI: 93.2%-98.8%) for IgA, and of 48.7% (95% CI: 33.9%-63.8%) and 98.7% (95% CI: 93.2%-99.8%) for IgM. With the Platelia system, the specificity and sensitivity were 97.4% (95% CI: 92.1%-99.7%) and 94.9% (95% CI: 87.7%-98.0%) for total antibodies using the adapted cut-offs. The NovaLisa and the Platelia tests have satisfactory analytical performances. The clinical performances are excellent for IgG, IgA, and total antibodies especially if the cut-off is optimized

Year of Publication: 2020
Contained in: Journal of medical virology (15.07.2020)
All journal articles: Search for all articles in this journal
Language: English
Contributors: Tré-Hardy, Marie | Author
Wilmet, Alain
Beukinga, Ingrid
Favresse, Julien
Dogné, Jean-Michel
Douxfils, Jonathan
Blairon, Laurent
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19, ELISA
IgA
IgG
IgM
Journal Article
SARS-CoV-2
antibodies
kinetics
ISSN: 1096-9071
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 09.09.2020
published: Print-Electronic
Citation Status Publisher
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32667733
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1002/jmv.26303
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03649nma a2200601 c 4500
001 NLM313360154
003 DE-601
005 20200909214724.0
007 cr uuu---uuuuu
008 200715s2020 000 0 eng d
024 7 |a 10.1002/jmv.26303  |2 doi 
028 5 2 |a pubmed20n1332.xml 
035 |a (DE-599)NLM32667733 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Tré-Hardy, Marie 
245 1 0 |a Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 09.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © 2020 Wiley Periodicals LLC. 
520 |a The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests is massive. The external validation of their performance is needed before use in clinical routine practice. Our study aims at assessing the analytical and clinical performance of two enzyme-linked immunosorbent assay tests detecting antibodies directed against the virus nucleocapsid protein: The NovaLisa SARS-CoV-2 immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) test (NovaTec) allowing a separate detection of each antibody and the Platelia SARS-CoV-2 Total Ab test (Bio-Rad) detecting total antibodies (IgM, IgA, and IgG). Two-hundred and eight coronavirus disease 2019 samples from 48 quantitative reverse transcription-polymerase chain reaction (RT-qPCR) confirmed patients were used to perform the sensitivity analysis. Non-SARS-CoV-2 sera (n = 79) with a potential cross-reaction to SARS-CoV-2 immunoassays were included in the specificity analysis. In addition, using receiver operator characteristic curves, adapted cut-off for improvement of the performances were proposed. The kinetics of these antibodies was also assessed over 8 weeks. Two weeks after the RT-qPCR positive detection, the NovaLisa test shows a sensitivity and specificity of 94.9% (95% confidence interval [CI]: 83.1%-98.6%) and 96.2% (95% CI: 89.4%-98.7%) for IgG, of 89.7% (95% CI: 76.4%-95.9%) and 98.7% (95% CI: 93.2%-98.8%) for IgA, and of 48.7% (95% CI: 33.9%-63.8%) and 98.7% (95% CI: 93.2%-99.8%) for IgM. With the Platelia system, the specificity and sensitivity were 97.4% (95% CI: 92.1%-99.7%) and 94.9% (95% CI: 87.7%-98.0%) for total antibodies using the adapted cut-offs. The NovaLisa and the Platelia tests have satisfactory analytical performances. The clinical performances are excellent for IgG, IgA, and total antibodies especially if the cut-off is optimized 
611 2 7 |a Journal Article  |2 gnd 
655 7 |a COVID-19, ELISA  |2 gnd 
655 7 |a IgA  |2 gnd 
655 7 |a IgG  |2 gnd 
655 7 |a IgM  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a antibodies  |2 gnd 
655 7 |a kinetics  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19, ELISA 
689 1 1 |a IgA 
689 1 2 |a IgG 
689 1 3 |a IgM 
689 1 4 |a SARS-CoV-2 
689 1 5 |a antibodies 
689 1 6 |a kinetics 
689 1 |5 DE-601 
700 1 |a Wilmet, Alain 
700 1 |a Beukinga, Ingrid 
700 1 |a Favresse, Julien 
700 1 |a Dogné, Jean-Michel 
700 1 |a Douxfils, Jonathan 
700 1 |a Blairon, Laurent 
773 0 8 |i in  |t Journal of medical virology  |g  (15.07.2020)  |w (DE-601)NLM000285676  |x 1096-9071 
856 4 1 |u http://dx.doi.org/10.1002/jmv.26303  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |j 2020  |b 15  |c 07